Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which is the most common cytochrome P450 enzyme associated with drug metabolism?

CYP3A4/5. **Explanation:** **1. Why CYP3A4/5 is the Correct Answer:** CYP3A4 is the most abundant and clinically significant cytochrome P450 isoform in humans. It accounts for approximately **30% of the total CYP content in the liver** and is responsible for the metabolism of nearly **50% of all clinically used drugs**. Its high expression in both the liver and the intestinal wall makes it a major determinant of first-pass metabolism and oral bioavailability. **2. Analysis of Incorrect Options:** * **CYP2D6 (Option B):** While it is the second most important enzyme and metabolizes about 25% of drugs (including beta-blockers, antidepressants, and opioids like codeine), it is highly **polymorphic**. It is not the most common by volume or total drug substrate count. * **CYP2C8/9 (Option C):** These metabolize roughly 15% of drugs. CYP2C9 is notable for metabolizing drugs with narrow therapeutic indices, such as **Warfarin** and **Phenytoin**. * **CYP2C19 (Option D):** This enzyme metabolizes about 5% of drugs, including **Clopidogrel** (a prodrug) and Proton Pump Inhibitors (PPIs). **3. High-Yield Clinical Pearls for NEET-PG:** * **Inducers of CYP3A4:** Rifampicin, Phenytoin, Carbamazepine, St. John’s Wort (Mnemonic: **GPRS Cell Phone** - Griseofulvin, Phenytoin, Rifampicin, Smoking, Carbamazepine, Phenobarbitone). * **Inhibitors of CYP3A4:** Ketoconazole, Erythromycin, **Grapefruit juice**, Ritonavir (Mnemonic: **VITAMIN K** - Valproate, Isoniazid, Troleandomycin, Amiodarone, Macrolides, Itraconazole, NNRTIs, Ketoconazole). * **Suicide Inhibitor:** Grapefruit juice irreversibly inhibits CYP3A4 in the intestinal wall. * **Genetic Polymorphism:** Most commonly associated with **CYP2D6** (Poor vs. Ultra-rapid metabolizers) and **CYP2C19**.

Q: Which of the following drugs does not cross the placenta?

Heparin. **Explanation:** The passage of drugs across the placental barrier is primarily determined by the drug's molecular weight, lipid solubility, and ionization state. **Why Heparin is the Correct Answer:** Heparin is a large, highly polar (negatively charged) polysaccharide molecule with a high molecular weight (approx. 15,000 Daltons). Due to its **large size and high degree of ionization**, it cannot cross the placental barrier. Consequently, heparin does not affect the fetus and is the **anticoagulant of choice during pregnancy**. **Why the Other Options are Incorrect:** * **Warfarin (Option B):** Unlike heparin, warfarin is a small, lipid-soluble molecule that easily crosses the placenta. It is highly teratogenic, especially during the first trimester, causing **Fetal Warfarin Syndrome** (characterized by nasal hypoplasia and stippled epiphyses). * **Dicoumarol (Option C) and Nicoumalone (Option D):** These are coumarin derivatives similar to warfarin. They are small molecules that cross the placenta and carry significant risks of fetal hemorrhage and teratogenicity. **NEET-PG High-Yield Pearls:** 1. **Rule of Thumb:** Drugs with a molecular weight **>1000 Daltons** generally do not cross the placenta. Heparin fits this criterion. 2. **LMWH (Low Molecular Weight Heparin):** Even though it is smaller than Unfractionated Heparin, LMWH (e.g., Enoxaparin) also **does not cross the placenta** and is frequently used in clinical practice for pregnant patients. 3. **Teratogenicity:** Warfarin is contraindicated in pregnancy (Category X), except in specific cases of high-risk mechanical heart valves, though even then, it is avoided near term due to the risk of intracranial hemorrhage during delivery.

Q: What is the mechanism of action of sildenafil?

Inhibits PDE 5. **Explanation:** **Correct Answer: C. Inhibits PDE 5** Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the vascular smooth muscle of the corpus cavernosum and pulmonary vasculature, Nitric Oxide (NO) activates guanylyl cyclase, which increases levels of **cyclic GMP (cGMP)**. PDE-5 is the enzyme responsible for the degradation of cGMP. By inhibiting PDE-5, sildenafil prevents the breakdown of cGMP, leading to prolonged smooth muscle relaxation and vasodilation. This results in increased blood flow to the penis (treating erectile dysfunction) and decreased pulmonary arterial pressure. **Why the other options are incorrect:** * **Option A (PDE-2):** PDE-2 inhibitors are primarily researched for cognitive enhancement and are not the target for sildenafil. * **Option B (PDE-4):** PDE-4 is mainly found in inflammatory cells. Inhibitors like **Roflumilast** are used in the treatment of COPD and severe asthma. * **Option D (PDE-3):** PDE-3 is found in cardiac muscle and blood vessels. Inhibitors like **Milrinone** and **Cilostazol** increase cAMP levels, acting as inotropes and vasodilators. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Erectile dysfunction and Pulmonary Arterial Hypertension (PAH). * **Contraindication:** Never co-administer with **Nitrates** (e.g., Nitroglycerin) as it can cause life-threatening hypotension due to synergistic increases in cGMP. * **Side Effects:** Headache, flushing, and **Cyanopsia** (blue-tinted vision) due to weak cross-inhibition of PDE-6 in the retina. * **Tadalafil** is a similar drug with a much longer half-life (the "weekend pill").

Q: What is pharmacokinetics?

The study of drug movement in the body. **Explanation:** **Pharmacokinetics** refers to the quantitative study of drug movement in, through, and out of the body. It essentially describes **"what the body does to the drug."** This process is governed by the **ADME** acronym: * **A**bsorption (entry into the blood) * **D**istribution (movement into tissues) * **M**etabolism (biotransformation, primarily in the liver) * **E**xcretion (elimination via kidneys or bile) **Analysis of Options:** * **Option A (Correct):** As defined above, pharmacokinetics tracks the concentration of a drug over time as it moves through various compartments. * **Option B (Incorrect):** This describes **Pharmacodynamics**, which is the study of the biochemical and physiological effects of drugs and their mechanisms of action (**"what the drug does to the body"**). * **Option C (Incorrect):** This refers to **Pharmacogenetics**, the study of how genetic variations influence individual responses to drugs (e.g., G6PD deficiency causing hemolysis with Primaquine). **NEET-PG High-Yield Pearls:** 1. **First-Pass Metabolism:** A key pharmacokinetic concept where a drug is metabolized (usually in the liver) before reaching systemic circulation, significantly reducing bioavailability (e.g., Nitroglycerin). 2. **Volume of Distribution (Vd):** A theoretical volume that relates the amount of drug in the body to its plasma concentration. Drugs with high Vd (like Digoxin) are sequestered in tissues and are not easily removed by hemodialysis. 3. **Half-life ($t_{1/2}$):** The time required for the plasma concentration to reduce by 50%. It takes approximately **4 to 5 half-lives** to reach a "steady state" or to completely eliminate a drug from the body.

Q: What is the half-life of digoxin?

40 hours. **Explanation:** **Correct Answer: B. 40 hours** Digoxin is a cardiac glycoside used primarily in the management of atrial fibrillation and heart failure. The half-life ($t_{1/2}$) of digoxin in a patient with normal renal function is approximately **36 to 40 hours**. This long half-life is a result of its extensive distribution into peripheral tissues (large volume of distribution) and its primary elimination via the kidneys through glomerular filtration and tubular secretion. **Analysis of Options:** * **A. 24 hours:** This is too short for digoxin. Drugs like Amiodarone (initial phase) or certain anticoagulants may fall in this range, but digoxin requires more time for plasma concentration to reduce by half. * **C & D. 48 and 60 hours:** While the half-life of digoxin can extend to **3–5 days (72+ hours)** in patients with **renal failure** (since it is 80% excreted unchanged in urine), 40 hours remains the standard physiological value for exam purposes. Digitoxin, a related glycoside, has a much longer half-life of 5–7 days. **High-Yield NEET-PG Clinical Pearls:** 1. **Steady State:** It takes approximately 4–5 half-lives to reach a steady state; for digoxin, this is roughly **7 days**. 2. **Therapeutic Window:** Digoxin has a narrow therapeutic index (0.5–2.0 ng/mL). Toxicity is common. 3. **Electrolyte Interactions:** **Hypokalemia**, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. 4. **Antidote:** Digoxin-specific antibody fragments (**DigiFab**) are used for life-threatening toxicity. 5. **P-glycoprotein:** Digoxin is a substrate of P-gp; drugs like **Quinidine, Verapamil, and Amiodarone** inhibit P-gp, increasing digoxin levels and risk of toxicity.

Q: If the apparent volume of distribution of a drug exceeds the total body fluid volume, which of the following is the most likely reason?

The drug is sequestered in body tissues.. **Explanation:** The **Apparent Volume of Distribution ($V_d$)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($V_d = \text{Total amount of drug} / \text{Plasma concentration}$). **1. Why Option A is correct:** If a drug is highly lipid-soluble or has a high affinity for specific tissues (e.g., adipose tissue, muscle, or bone), it leaves the vascular compartment and becomes **sequestered in tissues**. This results in an extremely low concentration of the drug in the plasma. Since $V_d$ is inversely proportional to plasma concentration, a very low plasma level yields a $V_d$ that exceeds the total body water (~42L). This indicates the drug is primarily stored outside the blood. **2. Why other options are incorrect:** * **Option B:** Elimination rate (half-life/clearance) describes how fast a drug leaves the body, not its anatomical distribution. * **Option C:** Poor plasma solubility might limit the dose administered, but $V_d$ specifically measures the ratio of distribution, not solubility limits. * **Option D:** If a drug is poorly bound to plasma proteins, more "free drug" is available to move into tissues, which *increases* $V_d$. However, the primary reason for a $V_d$ exceeding total body water is the active **tissue sequestration**, not just the lack of protein binding. **High-Yield Clinical Pearls for NEET-PG:** * **Digoxin:** Has a very high $V_d$ (~500L) because it binds strongly to cardiac and skeletal muscle. * **Chloroquine:** Has a massive $V_d$ (~13,000L) due to sequestration in the liver and retina. * **Hemodialysis:** Drugs with a high $V_d$ cannot be removed effectively by hemodialysis because most of the drug is hidden in tissues, not accessible in the blood. * **Loading Dose:** $V_d$ is the primary determinant used to calculate the loading dose ($LD = V_d \times \text{Target Plasma Concentration}$).

Q: What are the mechanisms of drug transport through biological membranes?

All of the above. **Explanation:** Drug transport across biological membranes is a fundamental pharmacokinetic process that determines absorption, distribution, and excretion. The correct answer is **"All of the above"** because drugs utilize multiple pathways depending on their lipid solubility, molecular size, and charge. 1. **Passive Diffusion (Option A):** This is the most common mechanism (approx. 90% of drugs). It occurs along a concentration gradient without energy expenditure. Lipid-soluble drugs dissolve in the membrane lipoid matrix to pass through, while small water-soluble drugs pass through aqueous pores. 2. **Facilitated Diffusion (Option B):** This involves a specific carrier protein that helps "facilitate" the movement of a drug across the membrane. Like passive diffusion, it follows a concentration gradient and does not require ATP, but it is saturable and subject to inhibition. 3. **Active Transport (Option C):** This requires energy (ATP) to move drugs *against* a concentration gradient. It is mediated by specific transporters (e.g., P-glycoprotein). This process is vital for the renal and biliary excretion of many drugs and for transport across the blood-brain barrier. **High-Yield Clinical Pearls for NEET-PG:** * **Fick’s Law:** Governs passive diffusion; the rate of diffusion is directly proportional to the concentration gradient and lipid solubility. * **P-glycoprotein (P-gp):** An efflux transporter (active transport) that pumps drugs out of cells. It is a major cause of multi-drug resistance in cancer cells. * **Saturability:** Unlike passive diffusion, both facilitated diffusion and active transport are **saturable** processes because they rely on a finite number of carrier proteins. * **Ion Trapping:** Only the **unionized** form of a drug is lipid-soluble and can cross membranes easily. This is why acidic drugs (like Aspirin) are better absorbed in the acidic environment of the stomach.

Q: A 70 kg patient needs to be started on nitroglycerine (NTG) infusion. A 5 ml ampoule contains 5 mg/ml NTG. One ampoule is added to normal saline to make a total of 500 ml solution. Calculate the infusion rate if NTG is required at a rate of 10 mcg/min. (1 micro drip = 60 drops/ml)

12 drops/min. ### Explanation This question tests your ability to perform clinical drug calculations, a high-yield skill for NEET-PG. To solve this, follow a step-by-step approach: **1. Calculate the Total Amount of Drug:** * Ampoule volume = 5 ml; Concentration = 5 mg/ml. * Total NTG = 5 ml × 5 mg/ml = **25 mg**. **2. Determine the Concentration of the Infusion:** * Total solution volume = 500 ml. * Concentration = 25 mg / 500 ml = 0.05 mg/ml. * Convert to micrograms: 0.05 mg × 1000 = **50 mcg/ml**. **3. Calculate the Infusion Rate in ml/min:** * Required dose = 10 mcg/min. * Rate (ml/min) = Dose required / Concentration = 10 mcg/min ÷ 50 mcg/ml = **0.2 ml/min**. **4. Convert to Drops/min:** * Standard micro drip set = 60 drops/ml. * Infusion rate = 0.2 ml/min × 60 drops/ml = **12 drops/min**. --- ### Analysis of Options * **A (12 drops/min): Correct.** Derived from the precise calculation of concentration (50 mcg/ml) and flow rate. * **B, C, and D:** These are incorrect. They typically result from calculation errors, such as forgetting to multiply the ampoule volume by its concentration (using 5 mg total instead of 25 mg) or using a standard macro drip (15-20 drops/ml) instead of the specified micro drip. --- ### Clinical Pearls for NEET-PG * **Nitroglycerine (NTG):** A venodilator at low doses; causes arterial dilation at higher doses. * **Indication:** Acute Coronary Syndrome (ACS), Acute Decompensated Heart Failure, and Hypertensive Emergency. * **Pharmacokinetics:** NTG has a very short half-life (~1–3 minutes), necessitating continuous infusion. * **Storage Note:** NTG is adsorbed by PVC plastic; ideally, non-PVC administration sets should be used to ensure accurate delivery. * **Tachyphylaxis:** Continuous use leads to nitrate tolerance within 24 hours due to the depletion of free sulfhydryl groups.

Question 1

Which is the most common cytochrome P450 enzyme associated with drug metabolism?

Accepted Answer

CYP3A4/5

Answer

CYP2D6

Answer

CYP2C8/9

Answer

CYP2C19

Question 2

Which of the following drugs does not cross the placenta?

Accepted Answer

Heparin

Answer

Warfarin

Answer

Dicoumarol

Answer

Nicoumalone

Question 3

What is the mechanism of action of sildenafil?

Accepted Answer

Inhibits PDE 5

Answer

Inhibits PDE 2

Answer

Inhibits PDE 4

Answer

Inhibits PDE 3

Question 4

What is pharmacokinetics?

Accepted Answer

The study of drug movement in the body

Answer

The study of drug effects

Answer

The study of drug responses, governed by heredity

Answer

None of the above

Question 5

What is the half-life of digoxin?

Accepted Answer

40 hours

Answer

24 hours

Answer

48 hours

Answer

60 hours

Question 6

If the apparent volume of distribution of a drug exceeds the total body fluid volume, which of the following is the most likely reason?

Accepted Answer

The drug is sequestered in body tissues.

Answer

The drug is slowly eliminated from the body.

Answer

The drug is poorly soluble in plasma.

Answer

The drug is poorly bound to plasma proteins.

Question 7

Which of the following is NOT true about non-competitive inhibition?

Accepted Answer

Potency is reduced.

Answer

Km is unchanged.

Answer

Vmax is reduced.

Answer

Binds to a site other than the active site.

Question 8

What are the mechanisms of drug transport through biological membranes?

Accepted Answer

All of the above

Answer

Passive diffusion

Answer

Facilitated diffusion

Answer

Active transport

Question 9

A 70 kg patient needs to be started on nitroglycerine (NTG) infusion. A 5 ml ampoule contains 5 mg/ml NTG. One ampoule is added to normal saline to make a total of 500 ml solution. Calculate the infusion rate if NTG is required at a rate of 10 mcg/min. (1 micro drip = 60 drops/ml)

Accepted Answer

12 drops/min

Answer

14 drops/min

Answer

15 drops/min

Answer

16 drops/min

Question 10

Succinylcholine is short-acting due to which of the following mechanisms?

Accepted Answer

Rapid hydrolysis

Answer

Rapid excretion

Answer

Poor absorption

Answer

None of the above

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?